NanoVibronix Presents UroShield Clinical Study At The University Of Michigan
Portfolio Pulse from Benzinga Newsdesk
NanoVibronix, Inc. (NASDAQ:NAOV) announced the start of the pilot phase of a clinical trial for its UroShield device at the University of Michigan. This trial is part of a broader study to further validate the efficacy of UroShield.
May 22, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NanoVibronix, Inc. (NASDAQ:NAOV) has initiated the pilot phase of a clinical trial for its UroShield device at the University of Michigan. This trial aims to provide further clinical evidence of the device's efficacy.
The initiation of the clinical trial's pilot phase is a significant step for NanoVibronix as it seeks to validate the efficacy of its UroShield device. Positive results from this trial could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100